Click on a filter below to refine your search. Remove a filter to broaden your search.
Exposures to PM2.5 and NO2 was linked to increased risk for COVID-19-related hospitalization, with and without adjustment for vaccination.
In a two-part vote, the panel voted 10-to-2 in favor of the vaccine’s safety and unanimously on the shot’s effectiveness.
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
A second booster dose resulted in 123,869 fewer hospitalizations and 5,524 fewer deaths versus a single-dose campaign.
Natural immunity, however, was tied to a lower incidence of new infection.
No significant difference was seen in hospitalization for pneumonia or influenza or in hospitalization for any cause or mortality.
The changes include a recommendation for all adults to receive a dose of the new COVID-19 vaccine and RSV vaccination.
Changes include a new section relating to COVID-19 vaccines and the addition of a newly licensed vaccine for hepatitis B.
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals were hesitant about booster doses.
An efficacy of 92% was found among at-risk COVID-19-unvaccinated individuals with type 1 diabetes.